• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    CorVel (CRVL) Valuation Check After Mixed Returns And A 51% One Year Shareholder Loss

    Simply Wall St·04/02/2026 23:33:59
    Listen to the news

    What recent returns suggest about CorVel (CRVL)

    CorVel (CRVL) has had mixed share price moves, with gains of 1.6% over the past week and about 4.3% over the past month, set against a roughly 17.2% decline in the past 3 months.

    See our latest analysis for CorVel.

    The recent 4.3% 1 month share price return contrasts with a 17.2% share price decline year to date and a 51.0% 1 year total shareholder return loss. This suggests momentum has cooled after a stronger multi year total return profile.

    If CorVel’s recent moves have you reassessing your watchlist, this can be a good moment to widen the search and look at 20 top founder-led companies

    With CorVel trading at an implied intrinsic discount of about 43%, investors are left asking whether the current price underestimates its workers’ compensation and claims management business, or whether the market already reflects its future growth potential.

    Preferred P/E of 26.3x: Is it justified?

    CorVel is trading on a P/E of 26.3x, which sits below a peer average of 50.3x but above the broader US Healthcare industry at 22x.

    The P/E ratio compares the current share price to earnings per share. It effectively shows how much investors are paying today for each dollar of current earnings. For a company focused on workers’ compensation and claims management, a higher P/E can sometimes indicate that the market is placing value on consistent profitability and cash generation rather than rapid growth forecasts.

    In this context, CorVel’s P/E of 26.3x is framed as good value compared with its direct peers at 50.3x. This points to a lower price tag for similar earnings power within that peer set. At the same time, the stock is described as expensive relative to the wider US Healthcare industry average of 22x, which implies the market is still willing to pay a premium over the sector as a whole for its earnings profile.

    Result: Price-to-earnings of 26.3x (ABOUT RIGHT)

    See what the numbers say about this price — find out in our valuation breakdown.

    However, there is still the risk that a 51.0% 1 year total return loss and a 17.2% year to date decline signal deeper concerns about CorVel’s earnings quality or sector sentiment.

    Find out about the key risks to this CorVel narrative.

    Another view: what the cash flows say

    While the P/E of 26.3x suggests CorVel is cheaper than peers but pricier than the wider US Healthcare group, our DCF model points in a different direction. At $54.46 versus an estimated future cash flow value of $95.76, the shares screen as materially undervalued. This raises a clear question: is the price or the cash flow view out of line?

    Look into how the SWS DCF model arrives at its fair value.

    CRVL Discounted Cash Flow as at Apr 2026
    CRVL Discounted Cash Flow as at Apr 2026

    Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out CorVel for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 62 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

    Next Steps

    Mixed signals on price, value and sentiment can be confusing, so do not wait to form an opinion based only on headlines. Instead, check the full picture with 2 key rewards and 1 important warning sign

    Looking for more investment ideas?

    If CorVel is already on your radar, now is the time to broaden your horizons and let high quality data point you toward your next opportunity.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.